Our COVID Vaccine Statement and other related resources for patients and our researchers and research staff are available on the COVID-19 Updates webpage.
Quynh-Nhu Nguyen, MD
Open to Accrual
August 17, 2020
Most Recent Amendment
June 2, 2021
To compare investigator-assessed progression free survival (PFS) between atezolizumab plus radiotherapy and atezolizumab alone
To compare overall survival (OS) between atezolizumab plus radiotherapy and atezolizumab alone
Patients with pathologically proven diagnosis of extensive stage small cell lung cancer (ES-SCLC), stable disease (SD) or partial response (PR) after 4-6 cycles of etoposide/platinum (E/P) doublet plus atezolizumab
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.